Kerala

AOC

Goods

Chemicals/Minerals

e-tender for the procurement of Anti Haemophilia drugs for the year 2023-24

Kerala Medical Services Corporation Ltd

Thiruvananthapuram, Kerala

Amount: Refer DocsCloses: 3 Oct 2023Closed

Bids

4 Bids24 Mar 2025

#	Company	Amount	Rank	Status
1	L1₹4.1 CrAccepted-AOC 1ST AND 2ND FLOOR NXT TOWER 2 EMBASSY MANYATA BUSINESS PARK NAGAVARA VILLAGE KASABA HOBLI BANGALORE KARNATAKA INDIA 560045 \| BANGALORE \| BANGALORE \| KARNATAKA \| 560045	₹4.1 Cr	L1	Accepted-AOC DETAILS IN NOTICE
2	L1₹17.6 CrAccepted-AOC 6TH FLOOR BUILDING NO 8 TOWER C DLF CYBER CITY PHASE II MOTI NAGAR GURGAON WEST DELHI DELHI 122002 \| GURUGRAM \| HARYANA \| 122002	₹17.6 Cr	L1	Accepted-AOC DETAILS IN NOTICE
3	NO L1Rejected-AOC	-	NO L1	Rejected-AOC DETAILS IN NOTICE
4	Rejected-Technical CORPORATE HOUSE NEAR SOLA BRIDGE S G HIGHWAY THALTEJ AHMEDABAD GUJARAT 380054 \| AHMADABAD \| GUJARAT \| 380054	-	-	Rejected-Technical Details in notice

Tender Value

Refer Docs

EMD Value

₹50,000

Closing Date

3 Oct 2023, 5:00 pmClosed

Tender Inviting Organisation

Name

Managing Director

Address

KMSCL, Thycaud, Thiruvananthapuram

Work Description

e-tender for the procurement of Anti Haemophilia drugs for the year 2023-24

Tender Information

Tender ID

2023_KMSCL_601583_1

Reference Number

KMSCL/ED/HAEM/RC/2023/014

Tender Type

Open Tender

Product Category

Chemicals/Minerals

Period of Work

365 days

Location

Thiruvananthapuram

Source Website

Subscribe to view

Eligibility / Pre-Qualification

Please refer tender document

Documents Required

31 documents required · 31 mandatory

Fee/PreQual/Technical

RequiredCheck list in Anx1 (.pdf)

RequiredThe details of offline EMD submitted as per the sl no 2 of Anx 1 (.pdf)

RequiredThe details of Re inspection fee as per sl no 3 of Anx 1 (.pdf)

RequiredThe details of factory inspection fee as per sl no 4 of Anx 1 (.pdf)

RequiredBid offer form in the format as per the sl no 5 of Anx 1 (.pdf)

RequiredBid offer form in the format as per the sl no 6 of Anx 1 (.xls)

RequiredNotary attested copy of Average Annual Turn over as per sl no 7 of Anx 1 (.pdf)

RequiredNotary attested copy of original manufaturing license as per sl no 8 of Anx 1 (.pdf)

RequiredNotary attested copy of valid import license as per sl no 9 of Anx.1 (.pdf)

RequiredNotary attested copy of product wise Market standing certificate as per sl no 10 of Anx 1 (.pdf)

RequiredNotary attested copy of valid license for the sale of drugs as per sl no 11 of Anx 1 (.pdf)

RequiredNotary attested copy of valid WHO GMP certificate as per sl no 12 of An x1 (.pdf)

RequiredNotary attested copy of valid COPP issued as per the sl no 13 of An x1 (.pdf)

RequiredNotary attested copy of relevant document as per the sl no 14 of Anx 1 (.pdf)

RequiredNotary attested copy of statement as per the sl no 15 of Anx 1 (.pdf)

RequiredNotary attested copy of relevant document as per sl no 16 of Anx 1 (.pdf)

RequiredNotary attested copy of statement as per sl no 17 of Anx 1 (.pdf)

RequiredNotary attested copy of relevant document as per sl no 18 of Anx1 (.pdf)

RequiredNotary attested copy of statement as per sl no 19 of Anx 1 (.pdf)

RequiredNotary attested copy of relevant documents as per sl no 20 of Anx 1 (.pdf)

RequiredNotary attested copy of details of batches as per sl no 21 of Anx 1 (.pdf)

RequiredNotary attested copy of statement as per sl no 22 of Anx 1 (.pdf)

RequiredNotary attested documents as per sl no 23 of Anx 1 (.pdf)

RequiredNotary attested copy of current non conviction certificate as per sl no 24 of Anx 1 (.pdf)

RequiredNotary attested statement of performance certificate as per sl no 25 of Anx 1 (.pdf)

Requirednotary attested copy of Power of Attorney as per sl no 26 of Anx 1 (.pdf)

RequiredNotary attested copy undertaking as per sl no 27 of Anx 1 (.pdf)

RequiredNotary attested copy of Audited Balance sheet as per sl no 28 of Anx 1 (.pdf)

RequiredNotary attested details of technical personnel as per sl no 29 of Anx 1 (.pdf)

RequiredNotary attested details of the bidder as per sl no 30 of Anx 1 (.pdf)

Finance

RequiredPrice Bid Format (.xls)

Fee & Financial Details

Tender Fee Amount

₹29,500

Tender Fee Exemption Allowed

Yes

EMD Fee Amount

₹50,000

EMD Fee Exemption Allowed

Yes

Important Dates

Last Activity

24 Mar 2025

Published

11 Sept 2023

Bid Opening

7 Oct 2023

Download Starts

11 Sept 2023

Download Ends

3 Oct 2023

Submission Starts

11 Sept 2023

Clarification Period

11 Sept 2023 - 3 Oct 2023

BOQ Preview

•

ANTI HAEMOPHILIC FACTOR VIII with VON WILLIBRAND FACTOR 250 IU (contains Factor VIII 250 IU along with minimum 50% of VWF)

•

ANTI HAEMOPHILIC FACTOR VII 1 mg (50,000 IU)

•

HUMAN ANTI HAEMOPHILIC FACTOR IX 600 IU

•

FACTOR VIII INHIBITOR BYPASSING AGENT (FEIBA) 500 U

•

TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED

•

Novo Nordisk India Private Limited

Stage Documents

Technical Bid Opening

tech_bid_open.pdf

PDF

Technical Evaluation

tech_eval.pdf

PDF

Financial Bid Opening

fin_bid_open.pdf

PDF

boq_comp_chart.xlsx

xlsx

Financial Evaluation

fin_eval.pdf

PDF

Award of Contract

aoc.pdf

PDF

Ready to Participate?

Download all tender documents and submit your bid